|
--------------------------------------------------------------------------------------------------------
BIOAVAILABILITY AND BIOEQUIVALENCE: The Basics
and Beyond //
--------------------------------------------------------------------------------------------------------
* Enrollment for this unique
and highly rated "BABE" course is limited so
please REGISTER
early.
COURSE
DESCRIPTION //
-------------------------------------
For the most part, the decision to deem two
different drug formulations as "bioequivalent"
depends on the outcome of properly conducted
bioavailability studies in healthy human
volunteers. Although the key measures of
bioavailability, namely the rate and extent of
absorption are easily obtained, the broader issue
of bioequivalence assessment remains contentious
and controversial. Perhaps reflecting this state
of uncertainty, various procedures and standards
for determining bioequivalence have been
promulgated over the past two decades by
government regulatory agencies worldwide.
Fortunately, thanks to international harmonization
efforts, current bioavailability/ bioequivalence
guidelines issued in North America and Europe at
least now have many common elements.
Following an introduction to basic
pharmacokinetics, this comprehensive course, as
its alliterative title implies, will focus on
current as well as proposed "metrics" for
assessing bioequivalence. Skillfully presented
lectures and hands-on problem solving exercises
will provide attendees with a thorough
understanding of what is often perceived as an
esoteric and difficult area of applied
pharmacokinetics. This course has been
highly rated by both experienced and entry-level
regulatory, clinical and laboratory personnel from
generic AND research-based pharmaceutical
companies.
PARTIAL COURSE
CONTENTS //
----------------------------------------------
- Basic pharmacokinetics
principles
- Bioavailability
determinants (AUCt, AUCinf,
Cmax,Tmax, etc.)
- Design of both single
and multiple dose studies
- Mean versus individual
ratio analyses
- Confidence interval
calculations
- Food and other factors
affecting bioavailability
- Controlled release
formulations
- Cmax - Cmin
fluctuations
- Intrasubject
variability
- Drug
interchangeability ("prescribability" versus
"switchability")
- In vitro
dissolution as a predictor of bioequivalence
- Cmax/AUC and other
proposed metrics for drug absorption rate
- Instances of possible
use of metabolite data
- Therapeutic
equivalence
- US, Canadian (incl.
2010 revisions) & European regulatory
requirements
- Problem areas (e.g.
highly variable drugs, nonlinearity)
- "Hands-on"exercises
PRINCIPAL INSTRUCTOR
> Peter W.
Mullen, Ph.D.
FALL VENUE //
----------------------------------------------
November 14 - 16, 2012
Holiday Inn Toronto Airport
- East
600 Dixon Road
Toronto (Etobicoke), Ontario
M9W 1J1
To register for this course CLICK HERE.
|
|